摘要:
The present invention relates to a method of identifying sub-forms of acute myeloid leukemia (AML), said method comprising (a) determining protein expression levels of a plurality of proteins in a cohort of patients suffering from AML; and (b) classifying said patients according to said protein expression levels; thereby obtaining classes of patients which define sub-forms of AML.
摘要:
The present invention relates to novel beta-lactone inhibitors of hydrolytic enzymes and their medical use, in particular a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in therapy. The present invention further relates to a pharmaceutical composition comprising the compound of formula (I) as defined herein and a pharmaceutically acceptable excipient. The instant compounds and compositions are useful in the treatment or prevention of cancer, an infectious disease, an inflammatory disease, or an autoimmune disease, and are useful as proteasome inhibitors. The present invention further relates to a plant protection composition comprising a compound of formula (I) or an agriculturally acceptable salt thereof, and to a method of controlling a plant disease, the method comprising applying a compound or composition according to the invention. The present invention further relates to a disinfectant comprising the compound of formula (I) and to the non-therapeutic use of the instant compounds or disinfectants for disinfecting or sterilizing an inanimate object.
摘要:
The invention is based on the surprising finding that in women with polycystic ovary syndrome (PCOS) an increased activity and/or expression of arginase is detected. The invention uses therefore various arginase associated biomarkers as indicators for the occurrence with the disease. More importantly the invention describes genetic variations associated with increased arginase expression/activity, and further being associated with PCOS. Hence, the invention provides enzymatic, immunological, and genetic diagnostic approaches for the detection and monitoring of PCOS in a subject. Furthermore the invention shows that the causal link of PCOS and arginase activity and hence provides the use of arginase inhibitors as a treatment approach.
摘要:
The present invention pertains to novel treatments for cancer diseases. Treatment of cancers with nucleoside analogs (NA), which specifically inhibit rapidly dividing cells, may face preexisting NA resistance or development of resistant cancer cells resulting in poor clinical prognosis. Treatment of cancers with oncolytic herpes simplex viruses (HSV) may face preexisting resistance or development of resistant cancer cells resulting in poor clinical prognosis. The invention overcomes chemotherapy resistance or resistance to oncolytic HSV by providing methods for detecting the resistance in a cancer disease based on the expression of SAM domain and HD domain-containing protein 1 (SAMHD1) in cancer cells. Furthermore provided are treatment options addressing the chemotherapy resistance such as a combination of a SAMHD1 inhibitor with a NA. Moreover, provided are treatment options addressing the resistance to oncolytic HSV such as a combination of a SAMHD1 inhibitor or depletion of SAMHD1 with an oncolytic HSV. The invention provides new medicines and companion diagnostics supporting clinical treatment decisions.
摘要:
The present invention provides novel non-coding RNAs (lncRNA) that were identified to be expressed in pericytes upon hypoxia. The lncRNA of the invention positively affect Platelet-derived Growth Factor Receptor (PDGFR) beta expression, pericytes proliferation and pericyte recruitment to endothelial cells. The invention provides inhibitors of the lncRNA for use in the treatment of diseases mediated by PDGFR expression. For example the invention described antisense approaches to target the lncRNA of the invention. Furthermore, the invention provides lncRNA inhibitors as amplifier of therapeutic PDGFR inhibitors such as imatinib or other tyrosine kinase inhibitors. lncRNA inhibitors and methods for screening modulators of lncRNA expression and/or function are provided.
摘要:
The present invention pertains to an improved mesenchymal stromal cell (MSC) preparation and a method for producing the same. The invention provides a new strategy to isolate MSC from bone marrow mononuclear cells (BM-MNCs) by pooling BM-MNCs of multiple unrelated (third-party) bone marrow donors. The MSC preparation manufactured in accordance with the methodology of the invention is characterized by a stable proliferative capability and an increased immunosuppressive potential when compared to individual donor MSC preparations or a pool of individual MSCs generated from multiple donors. The MSCs prepared according to the invention are particularly useful for medical applications such as the treatment of graft-versus-host disesase (GvHD) in recipients with hematopoietic stem cell transplants, patients with autoimmune disorders and as a cell-based therapy in regenerative medicine.
摘要:
Provided is a method for analyzing a polymerization reaction in a sample. The method comprises the steps of providing for fluorescent particles in the sample, exciting the fluorescence of the fluorescent particles, disturbing the sample for making the fluorescent particles move within the sample, taking images of the fluorescent particles within the sample, determining, for each of at least some of the images taken, a measure being indicative of the movement of the particles within the time period during which the respective image has been taken, and analyzing the polymerization reaction based on the determined measure.
摘要:
The invention relates to a device and method for providing a hyperpolarised liquid contrast agent for use in an MRI apparatus, in particular for administering to a living being (14) in an MRI apparatus, comprising the following steps: conducting the liquid contrast agent through a pipe (34) that extends along a longitudinal axis of an MW resonator (16) that is arranged in the magnetic field of the MRI apparatus, coupling a microwave having a frequency of at least 40 GHz into the MW resonator (16), said microwave being suitable for polarising, by means of DNP, the liquid contrast agent as it flows through the pipe (34) in the MW resonator (16), wherein the contrast agent is polarised at least in phases in a continuous through-flow in the MW resonator (16) and is administered directly, wherein an MW mode is formed in the MW resonator, which along at least the majority of the longitudinal axis of the resonator has a bulge in the magnetic field strength and a node in the electrical field strength, and wherein the power of the introduced microwave and the coupling of the microwave into the resonator (16) are matched such that an amplitude of the MW magnetic field strength (formula I) is produced in the region of at least one section of the power; wherein T 1,e is the relaxation time of the DNP active electrons.